NextBillion - An Initiative of the William Davidson Institute at the University of Michigan

Thursday, June 25, 2015

Last time we heard about Vasalgel, the male contraceptive that is expected to be the first one of its kind to be approved by the FDA, there was hope that it could be available to the public as soon as 2017. It’s now expected to hit the US market at least a year later, but there could be even more options for male birth control by then.

Vasalgel is the first treatment to lead the way. It’s non-hormonal, expected to last for years and would be administered via injection. As The Telegraph reports:

Vasalgel is essentially a polymer that’s injected under local anesthetic into the man’s sperm-carrying tubes, accessible through the scrotum—not in his penis or testicles as some authors have erred. It works by blocking sperm and is expected to be reversible through a second injection that dissolves the polymer.